{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:58:23Z","timestamp":1787068703978,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,8,7]],"date-time":"2012-08-07T00:00:00Z","timestamp":1344297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00213-012-2815-9","type":"journal-article","created":{"date-parts":[[2012,8,6]],"date-time":"2012-08-06T11:37:56Z","timestamp":1344253076000},"page":"329-339","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of dopamine D2\/D3 and serotonin 5-HT2A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography"],"prefix":"10.1007","volume":"225","author":[{"given":"Shunsuke","family":"Nakazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Horisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mizuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Onoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,7]]},"reference":[{"key":"2815_CR1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","volume":"205","author":"AI Abbas","year":"2009","unstructured":"Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (2009) Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 205:119\u2013128","journal-title":"Psychopharmacology (Berl)"},{"key":"2815_CR2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/sj.npp.1300390","volume":"29","author":"RA Bantick","year":"2004","unstructured":"Bantick RA, Rabiner EA, Hirani E, de Vries MH, Hume SP, Grasby PM (2004) Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology 29:847\u2013859","journal-title":"Neuropsychopharmacology"},{"key":"2815_CR3","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1017\/S146114571000009X","volume":"13","author":"A Bortolozzi","year":"2010","unstructured":"Bortolozzi A, Masana M, D\u00edaz-Mataix L, Cort\u00e9s R, Scorza MC, Gingrich JA, Toth M, Artigas F (2010) Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors. Int J Neuropsychopharmacol 13:1299\u20131314","journal-title":"Int J Neuropsychopharmacol"},{"key":"2815_CR4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00259-001-0683-3","volume":"29","author":"AF Chatziioannou","year":"2002","unstructured":"Chatziioannou AF (2002) Molecular imaging of small animals with dedicated PET tomographs. Eur J Nucl Med Mol Imaging 29:98\u2013114","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2815_CR5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3371\/CSRP.4.4.5","volume":"4","author":"L Citrome","year":"2011","unstructured":"Citrome L (2011) Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses 4:251\u2013257","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"2815_CR6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/BF00212840","volume":"94","author":"L Farde","year":"1988","unstructured":"Farde L, Pauli S, Hall H, Eriksson L, Halldin C, H\u00f6gberg T, Nilsson L, Sj\u00f6gren I, Stone-Elander S (1988) Stereoselective binding of 11C-raclopride in living human brain\u2014a search for extrastriatal central D2-dopamine receptors by PET. Psychopharmacology (Berl) 94:471\u2013478","journal-title":"Psychopharmacology (Berl)"},{"key":"2815_CR7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","volume":"452","author":"J Gonz\u00e1lez-Maeso","year":"2008","unstructured":"Gonz\u00e1lez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, L\u00f3pez-Gim\u00e9nez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC (2008) Identification of a serotonin\/glutamate receptor complex implicated in psychosis. Nature 452:93\u201397","journal-title":"Nature"},{"key":"2815_CR8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","volume":"60","author":"G Grunder","year":"2003","unstructured":"Grunder G, Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60:974\u2013977","journal-title":"Arch Gen Psychiatry"},{"key":"2815_CR9","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.bmc.2009.03.021","volume":"17","author":"MM Herth","year":"2009","unstructured":"Herth MM, Kramer V, Piel M, Palner M, Riss PJ, Knudsen GM, R\u00f6sch F (2009) Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg Med Chem 17:2989\u20133002","journal-title":"Bioorg Med Chem"},{"key":"2815_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ilar.49.1.17","volume":"49","author":"IJ Hildebrandt","year":"2008","unstructured":"Hildebrandt IJ, Su H, Weber WA (2008) Anesthesia and other considerations for in vivo imaging of small animals. ILAR J 49:17\u201326","journal-title":"ILAR J"},{"key":"2815_CR11","doi-asserted-by":"crossref","unstructured":"Horiguchi M, Huang M, Meltzer HY (2011) The role of 5-HT7 receptors in the phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. J Pharmacol Exp Ther. doi: 10.1124\/jpet.111.180638","DOI":"10.1124\/jpet.111.180638"},{"key":"2815_CR12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbr.2011.01.034","volume":"220","author":"T Horisawa","year":"2011","unstructured":"Horisawa T, Ishibashi T, Nishikawa H, Enomoto T, Toma S, Ishiyama T, Taiji M (2011) The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res 220:83\u201390","journal-title":"Behav Brain Res"},{"key":"2815_CR13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbr.2006.03.040","volume":"171","author":"XF Huang","year":"2006","unstructured":"Huang XF, Han M, Huang X, Zavitsanou K, Deng C (2006) Olanzapine differentially affects 5-HT2A and 2C receptor mRNA expression in the rat brain. Behav Brain Res 171:355\u2013362","journal-title":"Behav Brain Res"},{"key":"2815_CR14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/syn.890210107","volume":"21","author":"SP Hume","year":"1995","unstructured":"Hume SP, Opacka-Juffry J, Myers R, Ahier RG, Ashworth S, Brooks DJ, Lammertsma AA (1995) Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET. Synapse 21:45\u201353","journal-title":"Synapse"},{"key":"2815_CR15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002590050211","volume":"25","author":"SP Hume","year":"1998","unstructured":"Hume SP, Gunn RN, Jones T (1998) Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur J Nucl Med 25:173\u2013176","journal-title":"Eur J Nucl Med"},{"key":"2815_CR16","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","volume":"76","author":"J Ichikawa","year":"2001","unstructured":"Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001) 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521\u20131531","journal-title":"J Neurochem"},{"key":"2815_CR17","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","volume":"27","author":"RB Innis","year":"2007","unstructured":"Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533\u20131539","journal-title":"J Cereb Blood Flow Metab"},{"key":"2815_CR18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","volume":"334","author":"T Ishibashi","year":"2010","unstructured":"Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334:171\u2013181","journal-title":"J Pharmacol Exp Ther"},{"key":"2815_CR19","first-page":"208","volume":"39","author":"H Ito","year":"1998","unstructured":"Ito H, Nyberg S, Halldin C, Lundkvist C, Farde L (1998) PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. J Nucl Med 39:208\u2013214","journal-title":"J Nucl Med"},{"key":"2815_CR20","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.nucmedbio.2004.04.003","volume":"31","author":"EM Jagoda","year":"2004","unstructured":"Jagoda EM, Vaquero JJ, Seidel J, Green MV, Eckelman WC (2004) Experiment assessment of mass effects in the rat: implications for small animal PET imaging. Nucl Med Biol 31:771\u2013779","journal-title":"Nucl Med Biol"},{"key":"2815_CR21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0006-8993(00)02881-X","volume":"883","author":"T Kakiuchi","year":"2000","unstructured":"Kakiuchi T, Nishiyama S, Sato K, Ohba H, Nakanishi S, Tsukada H (2000) Age-related reduction of [11C]MDL100,907 binding to central 5-HT2A receptors: PET study in the conscious monkey brain. Brain Res 883:135\u2013142","journal-title":"Brain Res"},{"key":"2815_CR22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","volume":"158","author":"S Kapur","year":"2001","unstructured":"Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360\u2013369","journal-title":"Am J Psychiatry"},{"key":"2815_CR23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","volume":"156","author":"S Kapur","year":"1999","unstructured":"Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286\u2013293","journal-title":"Am J Psychiatry"},{"key":"2815_CR24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","volume":"157","author":"S Kapur","year":"2000","unstructured":"Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514\u2013520","journal-title":"Am J Psychiatry"},{"key":"2815_CR25","first-page":"968","volume":"77","author":"JH Kehne","year":"1996","unstructured":"Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 77:968\u2013981","journal-title":"J Pharmacol Exp Ther"},{"key":"2815_CR26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejphar.2008.06.063","volume":"591","author":"CS Knauer","year":"2008","unstructured":"Knauer CS, Campbell JE, Galvan B, Bowman C, Osgood S, Buist S, Buchholz L, Henry B, Wong EH, Shahid M, Grimwood S (2008) Validation of a rat in vivo [3H]M100907 binding assay to determine a translatable measure of 5-HT2A receptor occupancy. Eur J Pharmacol 591:136\u2013141","journal-title":"Eur J Pharmacol"},{"key":"2815_CR27","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.nucmedbio.2005.04.002","volume":"32","author":"MP Kung","year":"2005","unstructured":"Kung MP, Kung HF (2005) Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol 32:673\u2013678","journal-title":"Nucl Med Biol"},{"key":"2815_CR28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/nimg.1996.0066","volume":"4","author":"AA Lammertsma","year":"1996","unstructured":"Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. NeuroImage 4:153\u2013158","journal-title":"NeuroImage"},{"key":"2815_CR29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.tips.2010.06.002","volume":"31","author":"S Lancelot","year":"2010","unstructured":"Lancelot S, Zimmer L (2010) Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci 31:411\u2013417","journal-title":"Trends Pharmacol Sci"},{"key":"2815_CR30","first-page":"2266","volume":"32","author":"C Lemaire","year":"1991","unstructured":"Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L (1991) Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med 32:2266\u20132272","journal-title":"J Nucl Med"},{"key":"2815_CR31","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0006-3223(98)00187-5","volume":"44","author":"JA Lieberman","year":"1998","unstructured":"Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE (1998) Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44:1099\u20131117","journal-title":"Biol Psychiatry"},{"key":"2815_CR32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0024-3205(96)00013-6","volume":"58","author":"C Lundkvist","year":"1996","unstructured":"Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn CG, Carr AA, Brunner F, Farde L (1996) [11C]MDL 100907, a radioligland for selective imaging of 5-HT2A receptors with positron emission tomography. Life Sci 58:187\u2013192","journal-title":"Life Sci"},{"key":"2815_CR33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","volume":"161","author":"D Mamo","year":"2004","unstructured":"Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G (2004) A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161:818\u2013825","journal-title":"Am J Psychiatry"},{"key":"2815_CR34","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","volume":"164","author":"D Mamo","year":"2007","unstructured":"Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S (2007) Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164:1411\u20131417","journal-title":"Am J Psychiatry"},{"key":"2815_CR35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","volume":"25","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233\u2013255","journal-title":"Schizophr Bull"},{"key":"2815_CR36","first-page":"390","volume":"25","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee JC (1989) The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390\u2013392","journal-title":"Psychopharmacol Bull"},{"key":"2815_CR37","doi-asserted-by":"crossref","unstructured":"Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A (2011) Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. doi: 10.1176\/appi.ajp. 2011.10060907","DOI":"10.1176\/appi.ajp"},{"key":"2815_CR38","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543780903286388","volume":"18","author":"JM Meyer","year":"2009","unstructured":"Meyer JM, Loebel AD, Schweizer E (2009) Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 18:1715\u20131726","journal-title":"Expert Opin Investig Drugs"},{"key":"2815_CR39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/jcbfm.2010.83","volume":"31","author":"MS Milak","year":"2011","unstructured":"Milak MS, Severance AJ, Prabhakaran J, Kumar JS, Majo VJ, Ogden RT, Mann JJ, Parsey RV (2011) In vivo serotonin-sensitive binding of [11C]CUMI-101: a serotonin 1A receptor agonist positron emission tomography radiotracer. J Cereb Blood Flow Metab 31:243\u2013249","journal-title":"J Cereb Blood Flow Metab"},{"key":"2815_CR40","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","volume":"70","author":"M Nakamura","year":"2009","unstructured":"Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A (2009) Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatr 70:829\u2013836","journal-title":"J Clin Psychiatr"},{"key":"2815_CR41","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.npp.1300983","volume":"31","author":"S Natesan","year":"2006","unstructured":"Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S (2006) Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31:1854\u20131863","journal-title":"Neuropsychopharmacology"},{"key":"2815_CR42","doi-asserted-by":"crossref","unstructured":"Newman-Tancredi A, Kleven MS (2011) Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl). doi: 10.1007\/s00213-011-2247-y","DOI":"10.1007\/s00213-011-2247-y"},{"key":"2815_CR43","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1176\/ajp.152.10.1444","volume":"152","author":"AL Nordstr\u00f6m","year":"1995","unstructured":"Nordstr\u00f6m AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444\u20131449","journal-title":"Am J Psychiatry"},{"key":"2815_CR44","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/S0024-3205(00)80005-3","volume":"66","author":"Y Okubo","year":"2000","unstructured":"Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (2000) Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci 66:2455\u20132464","journal-title":"Life Sci"},{"key":"2815_CR45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0006-8993(94)91263-7","volume":"663","author":"H Onoe","year":"1994","unstructured":"Onoe H, Inoue O, Suzuki K, Tsukada H, Itoh T, Mataga N, Watanabe Y (1994) Ketamine increases the striatal N-[11C]methylspiperone binding in vivo: positron emission tomography study using conscious rhesus monkey. Brain Res 663:191\u2013198","journal-title":"Brain Res"},{"key":"2815_CR46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.neuroimage.2008.04.233","volume":"42","author":"D Perani","year":"2008","unstructured":"Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, Matarrese M, Carpinelli A, Bellodi L, Fazio F (2008) In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder. NeuroImage 42:306\u2013314","journal-title":"NeuroImage"},{"key":"2815_CR47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0924-977X(02)00031-7","volume":"12","author":"J Peuskens","year":"2002","unstructured":"Peuskens J, M\u00f6ller HJ, Puech A (2002) Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol 12:305\u2013310","journal-title":"Eur Neuropsychopharmacol"},{"key":"2815_CR48","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(05)63079-6","volume":"350","author":"LS Pilowsky","year":"1997","unstructured":"Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997) Limbic selectivity of clozapine. Lancet 350:490\u2013491","journal-title":"Lancet"},{"key":"2815_CR49","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1017\/S1461145709000042","volume":"12","author":"T Saijo","year":"2009","unstructured":"Saijo T, Maeda J, Okauchi T, Maeda J, Morio Y, Kuwahara Y, Suzuki M, Goto N, Suzuki K, Higuchi M, Suhara T (2009) Utility of small-animal positron emission tomographic imaging of rats for preclinical development of drugs acting on the serotonin transporter. Int J Neuropsychopharmacol 12:1021\u20131032","journal-title":"Int J Neuropsychopharmacol"},{"key":"2815_CR50","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/284472a0","volume":"284","author":"PR Sanberg","year":"1980","unstructured":"Sanberg PR (1980) Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 284:472\u2013473","journal-title":"Nature"},{"key":"2815_CR51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","volume":"425","author":"AW Schmidt","year":"2001","unstructured":"Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425:197\u2013201","journal-title":"Eur J Pharmacol"},{"key":"2815_CR52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0731-7085(97)00144-1","volume":"17","author":"DO Scott","year":"1998","unstructured":"Scott DO, Heath TG (1998) Investigation of the CNS penetration of a potent 5-HT2a receptor antagonist (MDL 100,907) and an active metabolite (MDL 105,725) using in vivo microdialysis sampling in the rat. J Pharm Biomed Anal 17:17\u201325","journal-title":"J Pharm Biomed Anal"},{"key":"2815_CR53","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","volume":"261","author":"P Seeman","year":"1976","unstructured":"Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic\/dopamine receptors. Nature 261:717\u2013719","journal-title":"Nature"},{"key":"2815_CR54","doi-asserted-by":"crossref","unstructured":"Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horv\u00e1th A, P\u00e1sztor G, Kap\u00e1s M, Gyerty\u00e1n I, Farkas S, Innis RB, Halldin C, Guly\u00e1s B (2011) Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology. doi: 10.1007\/s00213-011-2343-z","DOI":"10.1007\/s00213-011-2343-z"},{"key":"2815_CR55","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-67491-4","volume-title":"The brain of the common marmoset (Callithrix jacchus): a stereotaxic atlas","author":"H Stephan","year":"1980","unstructured":"Stephan H, Baron G, Schwerdtfeger WK (1980) The brain of the common marmoset (Callithrix jacchus): a stereotaxic atlas. Springer, Berlin"},{"key":"2815_CR56","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1176\/ajp.155.4.505","volume":"155","author":"C Trichard","year":"1998","unstructured":"Trichard C, Paill\u00e8re-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL (1998) Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 155:505\u2013508","journal-title":"Am J Psychiatry"},{"key":"2815_CR57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/1098-2396(200008)37:2<95::AID-SYN3>3.0.CO;2-H","volume":"37","author":"H Tsukada","year":"2000","unstructured":"Tsukada H, Harada N, Nishiyama S, Ohba H, Sato K, Fukumoto D, Kakiuchi T (2000) Ketamine decreased striatal [11C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis. Synapse 37:95\u2013103","journal-title":"Synapse"},{"key":"2815_CR58","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00213-011-2165-z","volume":"213","author":"K Varn\u00e4s","year":"2011","unstructured":"Varn\u00e4s K, Nyberg S, Karlsson P, Pierson ME, K\u00e5gedal M, Csel\u00e9nyi Z, McCarthy D, Xiao A, Zhang M, Halldin C, Farde L (2011) Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C]AZ10419369. Psychopharmacology 213:533\u2013545","journal-title":"Psychopharmacology"},{"key":"2815_CR59","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/00004647-200212000-00004","volume":"22","author":"Y Wu","year":"2002","unstructured":"Wu Y, Carson RE (2002) Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab 22:1440\u20131452","journal-title":"J Cereb Blood Flow Metab"},{"key":"2815_CR60","doi-asserted-by":"crossref","unstructured":"Yadav PN, Kroeze W, Farrell M, Roth BL (2011) Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther. doi: 10.1124\/jpet.111.183780","DOI":"10.1124\/jpet.111.183780"},{"key":"2815_CR61","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/syn.20766","volume":"64","author":"C Yokoyama","year":"2010","unstructured":"Yokoyama C, Yamanaka H, Onoe K, Kawasaki A, Nagata H, Shirakami K, Doi H, Onoe H (2010) Mapping of serotonin transporters by positron emission tomography with [11C]DASB in conscious common marmosets: comparison with rhesus monkeys. Synapse 64:594\u2013601","journal-title":"Synapse"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-012-2815-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-012-2815-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-012-2815-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T01:34:34Z","timestamp":1687656874000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-012-2815-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,7]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["2815"],"URL":"https:\/\/doi.org\/10.1007\/s00213-012-2815-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,7]]}}}